US4059692A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treating impaired consciousness with glutamyl-L-histidyl-L-prolinamide
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1976-03-22
•
Granted: 1977-11-22
•
Expires: 1996-03-22
Abstract
Abstract The impaired consciousness due to functional or organic damage of the brain in human patients can be significantly improved and restored, without any undesirable side-effect, by administering to the patients L-pyroglutamyl-L-histidyl-L-prolinamide or its physiologically acceptable salts.
Inventors
- 👤 Yoshinao Takahashi
- 👤 Kazuo Takeuchi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 14:43
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/06; A61K38/066; A61P; A61P25/00; A61P25/28
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
40 words
A method for the treatment of a human patient with impaired consciousness due to cranial trauma, brain surgery, cerebrovascular disorder, or brain tumor, which comprises administering to such patient an effective amount of L-pyroglutamyl-L-histidyl-L-prolinamide or a physiologically acceptable salt thereof.
Claim 2
Independent Claim
40 words
A method for the treatment of a human patient with impaired consciousness due to cranial trauma, brain surgery, cerebrovascular disorder, or brain tumor, which comprises administering to such patient an effective amount of L-pyroglutamyl-L-histidyl-L-prolinamide or a physiologically acceptable salt thereof.
Claim 3
Dependent Claim
20 words
A method as claimed in claim 1, wherein L-pyroglutamyl-L-histidyl-L-prolinamide or a physiologically acceptable salt thereof is administered parenterally or orally.
Claim 4
Dependent Claim
41 words
A method as claimed in claim 2, wherein L-pyroglutamyl-L-histidyl-L-prolinamide or a physiologically acceptable salt thereof is administered intravenously or intramuscularly in an amount of from about 100 to about 5,000 μg. in terms of free L-pyroglutamyl-L-histidyl-L-prolinamide per adult patient per day.
Claim 5
Dependent Claim
40 words
A method as claimed in claim 2, wherein L-pyroglutamyl-L-histidyl-L-prolinamide or a physiologically acceptable salt thereof is administered orally in an amount of from about 100 μg. to about 150 mg. in terms of free L-pyroglutamyl-L-histidyl-L-prolinamide per adult patient per day.
Claim 6
Dependent Claim
14 words
A method as claimed in claim 1, wherein the physiologically acceptable salt is tartrate.
References Cited (Backward Citations)
US3860570A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-11-21 | 1981-05-23 | 1981-11-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-11-21 | 1985-05-23 | 1985-11-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-11-21 | 1989-05-23 | 1989-11-22 | $7700.00 | Window Closed / Lapsed |